What Is in the Vitamin K Shot for Newborns?

The vitamin K shot given to newborns contains phytonadione, a synthetic form of vitamin K1 that is identical in structure to the vitamin K1 found naturally in green leafy vegetables.¹ It is delivered as a single intramuscular injection, typically into the baby’s thigh, within the first hours after birth. Beyond the active ingredient, the shot contains a handful of inactive ingredients that keep the fat-soluble vitamin suspended in a form the body can absorb, and those specifics are worth understanding for any parent who wants to know exactly what is going into their child.

Phytonadione, the Active Ingredient

Phytonadione goes by several names. You may see it called phytomenadione or simply vitamin K1 on a product label. All three names refer to the same molecule. It belongs to a family of fat-soluble vitamins grouped under the umbrella term “vitamin K,” but the form used in the newborn shot is specifically K1, the same type your body gets from foods like spinach, kale, and broccoli. The injectable version is manufactured to pharmaceutical-grade purity and dissolved into an emulsion so it can be injected into muscle tissue, where it absorbs steadily over time.

The standard dose in the United States is 1 milligram (1 mg) for a full-term newborn. In many European countries the same 1 mg intramuscular dose is standard as well, though some countries have historically used oral regimens instead. For a baby weighing around 3.5 kilograms, that 1 mg might sound like a lot compared to the trace amounts found in breast milk, and this disparity is one of the things that occasionally raises parental concern. But the dose was chosen because newborns start with almost no vitamin K stores and the injection needs to provide enough to last through the early weeks of life, when the baby’s own ability to produce and absorb the vitamin is still maturing.

The Inactive Ingredients

Because vitamin K1 does not dissolve in water on its own, the shot is formulated as an emulsion or a colloidal solution. The most common formulation in the U.S. uses polysorbate 80 as an emulsifier, which keeps tiny droplets of the fat-soluble vitamin evenly distributed in the aqueous solution. Propylene glycol acts as a solvent and stabilizer. Dextrose (a simple sugar) is sometimes included to make the solution more compatible with body fluids. Depending on the manufacturer, you may also find small amounts of benzyl alcohol as a preservative, though many newer formulations marketed specifically for neonatal use are preservative-free. Sodium hydroxide or hydrochloric acid may be present in trace amounts purely to adjust the pH so the injection is not too acidic or too alkaline for tissue.

None of these inactive ingredients are unique to the vitamin K shot. Polysorbate 80, for instance, appears in a wide range of injectable medications and some vaccines. Propylene glycol is used in numerous pharmaceutical products and is classified as generally recognized as safe by regulatory agencies. The amounts in a single 0.5 mL or 1 mL injection are extremely small. One detail worth noting: vitamin K1 is extremely sensitive to light, losing nearly half its potency after just two days of daylight exposure.² This is why the injectable form is packaged in amber glass ampules and stored away from light until the moment it is drawn up for administration.

Why Newborns Need It

Babies are born with very little vitamin K in their systems. There are several reasons for this gap. Vitamin K does not cross the placenta efficiently, so the mother’s own vitamin K levels do not translate into robust stores for the baby. On top of that, a newborn’s gut is essentially sterile at birth and only gradually colonized by bacteria, some of which eventually produce forms of vitamin K (called menaquinones). Until that bacterial ecosystem matures, the infant cannot generate its own supply. And breast milk, while excellent nutrition in nearly every other respect, contains quite low concentrations of vitamin K1.³

How low is breast milk’s vitamin K1 content? One study measured it at roughly 1.3 nanograms per milliliter, compared to about 52 nanograms per milliliter in standard infant formula.⁴ That is a roughly 40-fold difference. Formula-fed infants also showed substantially higher levels of vitamin K in their stool, suggesting more of the vitamin was making it through the digestive tract. Separately, research comparing breast-fed and formula-fed newborns found that formula-fed infants had circulating vitamin K1 levels in the normal adult range at every measurement point, while breast-fed infants lagged well behind without supplementation.⁵ This does not mean breastfeeding is inferior. It means that breastfed babies in particular benefit from the prophylactic shot, because their dietary intake alone is not enough to protect against bleeding in the early weeks.

What Vitamin K Actually Does in a Newborn’s Body

Vitamin K’s job is to activate a group of proteins that the body cannot use without it. Several of these proteins are clotting factors, the molecules that form a plug when a blood vessel is damaged. Without enough active clotting factors, even minor internal bleeding can become dangerous. The activation process works by chemically modifying certain amino acids on these proteins so they can bind calcium and participate in the clotting cascade.⁶ Vitamin K serves as an essential helper molecule in this reaction: it donates a chemical group that transforms the proteins from an inactive to an active form.⁷

After the vitamin K molecule participates in one round of activation, the body recycles it through what researchers call the vitamin K cycle, converting it back to its usable form so it can activate more proteins. This recycling means a single dose goes further than you might expect. In an adult with a normal diet, the cycle runs smoothly and vitamin K levels are rarely a concern. In a newborn with minimal stores, though, there is simply not enough vitamin K to keep the cycle running at the rate needed to maintain safe clotting factor levels. The intramuscular shot creates a depot of vitamin K1 in the muscle, which releases slowly into the bloodstream over days and weeks, bridging that gap until the infant’s diet and gut bacteria catch up.

What Happens Without the Shot

The condition the shot prevents is called vitamin K deficiency bleeding, or VKDB. It comes in three forms based on timing. Early VKDB occurs within the first 24 hours of life and is rare, usually linked to medications the mother was taking during pregnancy that interfere with vitamin K. Classic VKDB appears between days one and seven and typically involves bleeding from the umbilical stump, the gastrointestinal tract, or skin. Late VKDB is the most dangerous form, occurring between two weeks and six months of age. It often presents as intracranial bleeding, which can lead to permanent brain damage or death.

Late VKDB is uncommon when prophylaxis is given, but when parents decline the shot, the risk returns. Reports from the United States have documented a rise in late-onset VKDB cases tied directly to parental refusal of the injection.⁸ The consequences are stark: late VKDB often causes bleeding inside the skull with little or no warning. The shot has been standard practice since the 1940s precisely because it effectively eliminates this risk.⁹

Intramuscular Versus Oral Vitamin K

Some countries, and some parents, prefer an oral form of vitamin K instead of the injection. Oral vitamin K does prevent classic VKDB effectively, but its track record against late-onset VKDB is less reassuring. The American Academy of Pediatrics has pointed to multiple reports from countries that switched to oral prophylaxis and then saw cases of late-onset VKDB that would not have occurred with an intramuscular dose. Even multi-dose oral schedules, where the baby receives several doses over the first weeks of life, have not fully closed this gap.¹⁰

Part of the problem is absorption. Oral vitamin K1 depends on the infant’s gut to absorb a fat-soluble nutrient, and as noted earlier, the newborn gut is immature in ways that make absorption unpredictable. Another issue is compliance: a multi-dose oral regimen requires parents to remember and administer several doses over weeks, and missed doses leave the baby unprotected during the window when late VKDB is most likely. Oral vitamin K is still considered better than nothing and is widely used in Europe and by some clinicians in the U.S. when parents refuse the injection.¹¹ A Cochrane review noted that neither intramuscular nor oral vitamin K has been tested in randomized controlled trials specifically for late VKDB, which makes the evidence base imperfect, but observational data strongly favors the intramuscular route.¹²

The Cancer Scare and Why It Did Not Hold Up

In 1992, a small British study suggested a possible link between intramuscular vitamin K and childhood leukemia. The finding received widespread media coverage and prompted several countries to switch from injected to oral prophylaxis. The research community responded with a wave of larger, more rigorous studies. A pooled analysis of individual patient data from six case-control studies found no meaningful association between intramuscular vitamin K and leukemia, with an adjusted odds ratio of 1.09 and a confidence interval that straddled 1.0, meaning the effect was statistically indistinguishable from no effect at all.¹³ A separate large study from the United Kingdom Childhood Cancer Study reached the same conclusion: no association between the shot and leukemia or any other childhood cancer.¹⁴

The original study’s findings were never replicated. The scientific consensus today is firm: the vitamin K shot does not cause cancer. But the scare left a lasting shadow. Decades later, some parents still cite cancer risk as a reason for refusing the injection, even though the claim has been thoroughly investigated and rejected. Pediatricians dealing with hesitant families often find that this debunked association is still circulating on parenting forums and in alternative health communities.

Why Some Parents Refuse and What They Get Wrong

Research into parental refusal has identified several overlapping concerns. Some parents mistakenly refer to the vitamin K injection as the “vitamin K vaccine,” conflating it with routine immunizations and carrying over any vaccine-related anxieties they already have.¹⁵ The vitamin K shot is not a vaccine. It contains no weakened or inactivated virus, no immune-stimulating adjuvant, and does not interact with the immune system. It is a vitamin supplement delivered by injection.

Other parents worry about preservatives in the shot, particularly benzyl alcohol. As discussed earlier, many formulations designed for neonatal use are preservative-free, and this point can often be clarified by simply asking the hospital or birth center which product they stock. A third common concern is the perceived “high dose,” with some parents uncomfortable that a baby is receiving what seems like a large amount of a vitamin relative to body weight. The 1 mg dose was established based on decades of clinical experience balancing efficacy against the need to create an adequate depot of the vitamin, and vitamin K1 has an excellent safety profile even at higher doses. Severe allergic-type reactions to parenteral vitamin K1 are associated primarily with intravenous administration in adults, occurring at an estimated rate of about 3 per 10,000 IV doses, and the neonatal intramuscular shot is a different route entirely.¹⁶

Preterm Infants and Babies With Absorption Problems

The standard 1 mg dose is calibrated for a healthy, full-term newborn. For premature infants, who are smaller and whose organ systems are even less mature, dosing is less standardized. Some centers use a reduced dose of 0.3 mg to 0.5 mg for very low birth weight babies, but the evidence supporting any particular dose for preterm infants is thin. Similarly, babies born with liver disease, biliary atresia, or other conditions that impair fat absorption face a higher risk of vitamin K deficiency even after receiving the standard shot, because they may not be able to absorb and recycle the vitamin normally. Experts have noted that firm dosing recommendations for these populations are still lacking and need further study.¹⁷ These infants often receive additional vitamin K supplementation beyond the birth dose, monitored through blood tests that measure clotting factor activity.

How Vitamin K Prophylaxis Varies Around the World

Vitamin K prophylaxis is recommended by the World Health Organization and is included in national newborn care guidelines in most countries. A survey of low- and middle-income countries found that the majority had vitamin K prophylaxis written into their national guidelines, but only about half reported that administration at birth was widely practiced. Roughly half of respondents also reported that healthcare workers were trained in diagnosing and treating VKDB.¹⁸ In high-income countries, the shot is near-universal at hospital births, but home births and birth center deliveries sometimes have lower administration rates, particularly when families opt out.

The variation is not just about access. Some countries in Europe have long used oral regimens as their standard protocol, partly influenced by the 1992 cancer scare that temporarily shifted practice away from injections. The Netherlands, for example, uses a multi-dose oral regimen for breastfed infants. Denmark and other Scandinavian countries have gone back and forth between oral and intramuscular protocols over the decades. In the United States, Canada, and Australia, the intramuscular injection remains the dominant recommendation. The differences in approach mean that parents who move between countries or read international parenting advice may encounter conflicting information about what is “standard.”

What the Shot Does Not Contain

Given the confusion that sometimes arises, it is worth being explicit about what is not in the vitamin K shot. It contains no antigens, no viral material, no aluminum salts, and no thimerosal. It is not a blood product. It does not contain any genetically modified organisms. The phytonadione is synthesized from plant-derived precursors to produce a molecule chemically identical to natural vitamin K1. The injection volume is small, typically 0.5 mL to 1 mL, and it is given once. There is no booster schedule, no follow-up doses required for a healthy full-term infant, and no interaction with the routine childhood vaccination schedule.

Parents who want to verify exactly what is in their hospital’s vitamin K product can ask to see the package insert, which lists every active and inactive ingredient along with the manufacturer’s recommended storage and handling instructions. The inserts are also publicly available through FDA databases. For parents weighing their options, the evidence consistently points to the intramuscular shot as the safest and most effective way to protect a newborn from a rare but potentially devastating bleeding disorder.